Review Articles (434 articles)

In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.

[1]  M. Caligiuri,et al.  Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[4]  K. Metzeler,et al.  Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Brand,et al.  Risk score for outcome after allogeneic hematopoietic stem cell transplantation , 2009, Cancer.

[6]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[7]  K. Döhner,et al.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. , 2009, Blood.

[8]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[9]  T. Haferlach,et al.  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. , 2009, Blood.

[10]  U. Germing,et al.  Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. , 2009, Leukemia research.

[11]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[12]  H. Kantarjian,et al.  Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia , 2009, Cancer.

[13]  M. Caligiuri,et al.  Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[15]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[16]  H. Dombret,et al.  Brief Report Results and Discussion , 2022 .

[17]  L. Bullinger,et al.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. , 2009, Blood.

[18]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[19]  T. Haferlach,et al.  Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. , 2009, Blood.

[20]  Bas J. Wouters,et al.  Brief Report Results and Discussion , 2022 .

[21]  T. Pabst,et al.  Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis , 2009, British Journal of Cancer.

[22]  G. Ehninger,et al.  The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells , 2009, Haematologica.

[23]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[24]  D. Niederwieser,et al.  Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission , 2009, Leukemia.

[25]  B. Löwenberg,et al.  A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. , 2009, Blood.

[26]  S. Fröhling,et al.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B , 2009, Haematologica.

[27]  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2008, Blood.

[28]  W. Jędrzejczak,et al.  A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. , 2007, Blood.

[29]  R. Hills,et al.  REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS , 2009 .

[30]  E. Estey,et al.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. , 2009, Blood.

[31]  W. Hiddemann,et al.  Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Bloomfield,et al.  The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes , 2009 .

[33]  G. Garcia-Manero,et al.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  T. A. Lister,et al.  Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Kantarjian,et al.  Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations , 2008 .

[36]  P. Thall,et al.  Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. , 2008 .

[37]  Christoph Schmid,et al.  Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Christian Langer,et al.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Power,et al.  Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML , 2008, Bone Marrow Transplantation.

[40]  C. Volteau,et al.  Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Gajewski,et al.  A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. , 2008, Blood.

[42]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[43]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Caligiuri,et al.  Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  E. Estey,et al.  Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia , 2008, Cancer.

[46]  S. Fröhling,et al.  Chromosomal abnormalities in cancer. , 2008, The New England journal of medicine.

[47]  D. Grimwade,et al.  Development of minimal residual disease-directed therapy in acute myeloid leukemia. , 2008, Seminars in oncology.

[48]  J. Cornelissen,et al.  Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality. , 2008, Seminars in oncology.

[49]  K. Mrózek,et al.  Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. , 2008, Seminars in oncology.

[50]  A. Dickinson,et al.  Non‐HLA genetics and predicting outcome in HSCT , 2008, International journal of immunogenetics.

[51]  E. Holler,et al.  Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. , 2008, Blood.

[52]  K. Döhner,et al.  Molecular characterization of acute myeloid leukemia , 2008, Haematologica.

[53]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[54]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[55]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[56]  F. Craig,et al.  Flow cytometric immunophenotyping for hematologic neoplasms. , 2008, Blood.

[57]  B. Löwenberg,et al.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. , 2008, Blood.

[58]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[59]  T. Haferlach,et al.  Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. , 2008, Blood.

[60]  G. Ehninger,et al.  MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. , 2008, Blood.

[61]  R. Schlenk,et al.  HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[62]  M. Caligiuri,et al.  FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. , 2008, Blood.

[63]  T. Golub,et al.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.

[64]  R. Herrmann,et al.  A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial , 2008, BMC Cancer.

[65]  M. Sorror,et al.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. , 2007, Blood.

[66]  L. Leibovici,et al.  Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  F. Appelbaum,et al.  Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500) , 2007, American journal of hematology.

[68]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  E. Seifried,et al.  Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis , 2007, Transfusion.

[70]  B. Löwenberg,et al.  Acute myeloid leukemia and the position of autologous stem cell transplantation. , 2007, Seminars in hematology.

[71]  A. Mead,et al.  FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. , 2007, Blood.

[72]  T. Haferlach,et al.  Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. , 2007, Blood.

[73]  M. Poon.  The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. , 2007, Transfusion medicine reviews.

[74]  J. Mehta,et al.  Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. , 2007, Blood.

[75]  M. Caligiuri,et al.  Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. , 2007, Blood.

[76]  J. Bourhis,et al.  Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. , 2007, Blood.

[77]  P. Ljungman.  Risk assessment in haematopoietic stem cell transplantation: viral status. , 2007, Best practice & research. Clinical haematology.

[78]  J. Ritz,et al.  Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[79]  N. Russell,et al.  Advances in the understanding of susceptibility to treatment‐related acute myeloid leukaemia , 2007, British journal of haematology.

[80]  E. Estey,et al.  Acute myeloid leukemia and myelodysplastic syndromes in older patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Augustin Ferrant,et al.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.

[82]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[83]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[84]  C. Bloomfield,et al.  Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances , 2007, Current opinion in hematology.

[85]  E. Estey,et al.  Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). , 2007, Blood.

[86]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[87]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[88]  J. Bourhis,et al.  Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group , 2007, Leukemia.

[89]  M. Andersen,et al.  Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. , 2007, Hematology. American Society of Hematology. Education Program.

[90]  N. Kröger,et al.  Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome , 2006, Bone Marrow Transplantation.

[91]  K. Döhner,et al.  High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. , 2006, Blood.

[92]  S. Fröhling,et al.  Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.

[93]  L. Leibovici,et al.  Antibiotic prophylaxis in neutropenic patients , 2006, Cancer.

[94]  H. Gundacker,et al.  The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations , 2006, British journal of haematology.

[95]  Stefan Fröhling,et al.  Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[98]  N. Brown,et al.  Invasive fungal infections: a review of epidemiology and management options. , 2006, Journal of medical microbiology.

[99]  Yi Ning,et al.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.

[100]  E. Estey.  How did we get here from there , 2006 .

[101]  A. Burnett,et al.  Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. , 2006, Blood.

[102]  H. Dombret,et al.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.

[103]  J. Tchinda,et al.  Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[105]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[106]  M. de Lima,et al.  Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. , 2006, Seminars in hematology.

[107]  S. Fröhling,et al.  Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial , 2006, Leukemia.

[108]  Susan O'Brien,et al.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.

[109]  W. Hiddemann,et al.  1 KIT-D 816 mutations in AML 1-ETO positive AML are associated with impaired event-free and overall survival , 2005 .

[110]  M. Maris,et al.  Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  T. Brümmendorf,et al.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2004, Blood.

[112]  M. Santolaya,et al.  [Antibiotic prophylaxis in neutropenic patients]. , 2006, Revista medica de Chile.

[113]  N. Villamor,et al.  Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] , 2006, Leukemia.

[114]  M. Caligiuri,et al.  Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  J. Esteve,et al.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.

[116]  Bob Löwenberg,et al.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.

[117]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[118]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[119]  E. Estey,et al.  Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome. , 2005 .

[120]  C. Bloomfield,et al.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  H. Kantarjian,et al.  Outcome of patients with acute myelogenous leukemia after second salvage therapy , 2005, Cancer.

[122]  T. Naoe,et al.  Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis , 2005, Leukemia.

[123]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[124]  M. Vignetti,et al.  Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. , 2005, Blood.

[125]  L. Leibovici,et al.  Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients , 2005, Annals of Internal Medicine.

[126]  C. Bloomfield,et al.  Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. , 2005, Blood.

[127]  T. Naoe,et al.  Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission , 2005, Cancer.

[128]  C. Craddock,et al.  Biology and management of relapsed acute myeloid leukaemia , 2005, British journal of haematology.

[129]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  M. Fey,et al.  Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype , 2005, Clinical Cancer Research.

[131]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[132]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[133]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[134]  T. Lister,et al.  Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. , 2005, Cancer research.

[135]  J. Bennett,et al.  Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995) , 2005, Leukemia & lymphoma.

[136]  P. Rebulla.  A mini-review on platelet refractoriness. , 2005, Haematologica.

[137]  N. Kröger,et al.  Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning , 2005, Leukemia.

[138]  W. Hiddemann,et al.  Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. , 2005, Haematologica.

[139]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[140]  S. Fröhling,et al.  Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia , 2004, Leukemia.

[141]  M. Tallman,et al.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant , 2004, Bone Marrow Transplantation.

[142]  K. Döhner,et al.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  C. Bloomfield,et al.  Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  W. Hiddemann,et al.  Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  W. Hiddemann,et al.  Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia. , 2004, The New England journal of medicine.

[146]  H. Kantarjian,et al.  The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia , 2004, Cancer.

[147]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[148]  E. Cardonick,et al.  Use of chemotherapy during human pregnancy. , 2004, The Lancet. Oncology.

[149]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[150]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[151]  G. Peters,et al.  The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. , 2004, Blood.

[152]  R M Stone,et al.  Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome , 2004, Leukemia.

[153]  C. Bloomfield,et al.  Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[155]  S. Fröhling,et al.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  D. Neuberg,et al.  A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. , 2004, Blood.

[157]  C. Bloomfield,et al.  Cytogenetics in Acute Leukemia , 2022 .

[158]  M. Baccarani,et al.  Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. , 2004, Haematologica.

[159]  W. Hiddemann,et al.  Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML , 2004, Leukemia.

[160]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  A. Rohatiner,et al.  A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia , 2003 .

[162]  A. Nademanee,et al.  A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[163]  M. Fey,et al.  Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  E. Estey,et al.  Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. , 2003, Blood.

[165]  F. Cainelli,et al.  Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. , 2003, The Lancet. Oncology.

[166]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[167]  M. Caligiuri,et al.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. , 2003, Blood.

[168]  Augustin Ferrant,et al.  Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. , 2003, The New England journal of medicine.

[169]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.

[170]  S. Fröhling,et al.  Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.

[171]  H. Dombret,et al.  Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.

[172]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[173]  J. Reilly,et al.  Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.

[174]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[175]  W. Hiddemann,et al.  Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  Bob Löwenberg,et al.  Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.

[177]  Bob Löwenberg,et al.  Acute myeloid leukemia and acute promyelocytic leukemia. , 2003, Hematology. American Society of Hematology. Education Program.

[178]  W. Hiddemann,et al.  Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. , 2003, Blood.

[179]  D. Gilliland,et al.  Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.

[180]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[181]  B. Johansson,et al.  Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001 , 2002, Leukemia.

[182]  F. Appelbaum,et al.  Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. , 2002, Blood.

[183]  J. Cayuela,et al.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.

[184]  B. Pollock,et al.  A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[185]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[186]  W. Hiddemann,et al.  Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24‐color FISH , 2002, Genes, chromosomes & cancer.

[187]  A. Goldstone,et al.  The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial , 2002, British journal of haematology.

[188]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[189]  C. Earle,et al.  The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.

[190]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[191]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[192]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[193]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  S. Fröhling,et al.  Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  H. Dombret,et al.  A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup , 2002 .

[196]  D. Grimwade.  Screening for core binding factor gene rearrangements in acute myeloid leukemia , 2002, Leukemia.

[197]  C. Bloomfield,et al.  11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop † , 2002, Genes, chromosomes & cancer.

[198]  J. Rowley,et al.  International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy‐related myelodysplastic syndromes and acute leukemia: Overview report , 2002, Genes, chromosomes & cancer.

[199]  S. Jhanwar,et al.  Balanced chromosome abnormalities inv(16) and t(15;17) in therapy‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop † , 2002, Genes, chromosomes & cancer.

[200]  M. Slovak,et al.  21q22 balanced chromosome aberrations in therapy‐related hematopoietic disorders: Report from an International Workshop † , 2002, Genes, chromosomes & cancer.

[201]  T. Miyazaki,et al.  Efficacy of granulocyte colony‐stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study , 2002, British journal of haematology.

[202]  D. Fabbro,et al.  Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412 , 2002 .

[203]  S. Singhal,et al.  Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia , 2002, Bone Marrow Transplantation.

[204]  P. Thall,et al.  Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. , 2001, Blood.

[205]  J. Doroshow,et al.  Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.

[206]  M. Caligiuri,et al.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.

[207]  D. Grimwade.  The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[208]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[209]  J. Matthews,et al.  Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia , 2001, Leukemia.

[210]  R. Clark,et al.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[211]  J. Cervera,et al.  Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. , 2001, Leukemia research.

[212]  Edward J. Lee,et al.  Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. , 2001, Blood.

[213]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  I. Bernstein,et al.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.

[215]  M. Caligiuri,et al.  Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[217]  E. Estey.  Growth factors in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[218]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[219]  J M Rainey,et al.  Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[220]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[221]  Yu Shen,et al.  Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival , 2001, Leukemia & lymphoma.

[222]  A. Tefferi,et al.  Acute Leukemia during Pregnancy: A Single Institutional Experience with 17 Cases , 2001, Leukemia & lymphoma.

[223]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[224]  A. Baruchel,et al.  Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM) , 2000, Bone Marrow Transplantation.

[225]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21 , 2000 .

[226]  E. Freireich.  Supportive care for patients with blood disorders. , 2000, British journal of haematology.

[227]  D. Reinhardt,et al.  Primary myelosarcomas are associated with a high rate of relapse: report on 34 children from the acute myeloid leukaemia–Berlin–Frankfurt–Münster studies , 2000, British journal of haematology.

[228]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[229]  S. Chevret,et al.  Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[230]  E. Estey.  Treatment of relapsed and refractory acute myelogenous leukemia , 2000, Leukemia.

[231]  M. Seto,et al.  Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. , 2000, International journal of hematology.

[232]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.

[233]  C. Bloomfield,et al.  Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[234]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[235]  R. Gray,et al.  A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.

[236]  J. Reilly,et al.  c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia , 1999, British journal of haematology.

[237]  P F Thall,et al.  Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. , 1999, Blood.

[238]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[239]  H. Chaplin,et al.  Prevalence of HLA sensitization in female apheresis donors , 1999, Transfusion.

[240]  大里 元美.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2 α B gene associated with myeloblastic leukemias , 1999 .

[241]  F. Appelbaum,et al.  Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. , 1998, The New England journal of medicine.

[242]  H. Nieuwenhuis,et al.  Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells , 1998, Bone Marrow Transplantation.

[243]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.

[244]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[245]  C. Bloomfield,et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.

[246]  N. Gorin.  Autologous stem cell transplantation in acute myelocytic leukemia. , 1998, Blood.

[247]  P. Koistinen,et al.  Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group , 1998, Leukemia.

[248]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[249]  P. Hurteloup,et al.  A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). , 1998, Blood.

[250]  P. Hurteloup,et al.  A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients , 1998 .

[251]  Keith Wheatley,et al.  Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.

[252]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[253]  T. Barbui,et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.

[254]  M A Boogaerts,et al.  Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[255]  P. Thall,et al.  Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. , 1997, Blood.

[256]  P. Hurteloup,et al.  Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). , 1997, Blood.

[257]  C. Bloomfield,et al.  Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). , 1997, Blood.

[258]  D. Grimwade,et al.  What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML Trial , 1997, Bone Marrow Transplantation.

[259]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[260]  R. Gray,et al.  Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. , 1997, Blood.

[261]  R. Storb,et al.  Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. , 1997, Blood.

[262]  R. Strauss,et al.  Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[263]  C. Bloomfield,et al.  Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[264]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[265]  Edward J. Lee,et al.  Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. , 1997, Blood.

[266]  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. , 1997, The New England journal of medicine.

[267]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[268]  A. Ganser,et al.  A Randomized , Double-Blind , Placebo-Controlled , Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[269]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[270]  M. Grever,et al.  A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.

[271]  F. Mandelli,et al.  Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[272]  S. Pierce,et al.  Routine bone marrow exam during first remission of acute myeloid leukemia. , 1996, Blood.

[273]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[274]  K. Pritchard-Jones,et al.  Mutations in the Wilms' tumor gene WT1 in leukemias. , 1996, Blood.

[275]  O. Garson,et al.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.

[276]  D. Scheinberg,et al.  Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. , 1996, Leukemia.

[277]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[278]  A. Chetrit,et al.  A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. , 1995, Leukemia & lymphoma.

[279]  J. Bennett,et al.  A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.

[280]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[281]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[282]  R. Mertelsmann,et al.  GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). , 1995, Leukemia.

[283]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[284]  S. Feig,et al.  Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors , 1994, British journal of haematology.

[285]  M. Caligiuri,et al.  Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. , 1994, Cancer research.

[286]  P. Sonneveld,et al.  Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). , 1994, Leukemia.

[287]  E. Reynoso,et al.  Acute leukemia and pregnancy--fatal fetal outcome after exposure to idarubicin during the second trimester. , 1994, Acta oncologica.

[288]  M. Tallman,et al.  Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[289]  E. Estey,et al.  Treatment of therapy-related leukemia and myelodysplastic syndrome. , 1993, Hematology/oncology clinics of North America.

[290]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[291]  A. Hagemeijer,et al.  Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. , 1993, Blood.

[292]  A. Rimm,et al.  Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. , 1992, Blood.

[293]  T. Kyo,et al.  Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. , 1992, Blood.

[294]  C. Coltman,et al.  Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. , 1992, Leukemia.

[295]  A. Bartolucci,et al.  A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[296]  E. Estey,et al.  Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. , 1992, Leukemia.

[297]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.

[298]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[299]  F. Mandelli,et al.  A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia , 1991 .

[300]  B. Christensen,et al.  Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. , 1991, Leukemia.

[301]  J. Sierra,et al.  Pregnancy outcome in hematologic malignancies , 1991, Cancer.

[302]  F. Mandelli,et al.  A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. , 1991, European journal of cancer.

[303]  J. Gabrilove,et al.  Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. , 1991, Blood.

[304]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[305]  P. Fenaux,et al.  Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly. , 1990, Leukemia.

[306]  P. Desai,et al.  Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. , 1990, Leukemia.

[307]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[308]  J. Matthews,et al.  Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.

[309]  Caligiuri Ma,et al.  Pregnancy and leukemia. , 1989 .

[310]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[311]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[312]  M. Andreeff,et al.  Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. , 1989, Leukemia.

[313]  M. Caligiuri,et al.  Pregnancy and leukemia. , 1989, Seminars in oncology.

[314]  R. Larson,et al.  Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. , 1988, Blood.

[315]  G. Ellestad,et al.  Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. , 1988, Science.

[316]  T. Lipp,et al.  Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[317]  M. Keating,et al.  Acute myeloblastic leukemia with hyperleukocytosis: Risk factors for early mortality in induction , 1988, American journal of hematology.

[318]  F. Shepherd,et al.  Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[319]  R. Gray,et al.  PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.

[320]  H. Lazarus,et al.  High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[321]  C. Marshall,et al.  Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia , 1985, Nature.

[322]  D. Elliot,et al.  Electroconvulsive therapy. Pretreatment medical evaluation. , 1982, Archives of internal medicine.

[323]  J. Blom,et al.  Acute Leukemia During Pregnancy , 1980, Southern medical journal.

[324]  K. Rai,et al.  Acute myelocytic leukemia. , 1976, Archives of internal medicine.